Artículo
Comprando el artículo el PDF del mismo podrá ser descargado
Precio 19,34 €
Comprar ahora
array:22 [ "pii" => "S2530016424000855" "issn" => "25300164" "doi" => "10.1016/j.endinu.2024.05.003" "estado" => "S300" "fechaPublicacion" => "2024-06-01" "aid" => "1489" "copyright" => "SEEN y SED" "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Endocrinol Diabetes Nutr. 2024;71:271-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemAnterior" => array:18 [ "pii" => "S2530016424000715" "issn" => "25300164" "doi" => "10.1016/j.endinu.2024.03.003" "estado" => "S300" "fechaPublicacion" => "2024-06-01" "aid" => "1479" "copyright" => "SEEN y SED" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Endocrinol Diabetes Nutr. 2024;71:263-70" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Carcinoid crisis: The challenge is still there" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "263" "paginaFinal" => "270" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Crisis carcinoide: el desafío sigue ahí" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2054 "Ancho" => 2007 "Tamanyo" => 342353 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Top row: Contrast-enhanced computed tomography (CT). Arterial phase (A)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>portal phase (B). Enlarged liver due to multiple hepatic metastases. Bottom row: PET/CT with [<span class="elsevierStyleSup">68</span>Ga]Ga-DOTA-TOC (C)<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>with [<span class="elsevierStyleSup">18</span>F]FDG (D). C. Multiple liver metastases showing moderate overexpression of somatostatin receptors. D. Normal glucose metabolism is observed.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Fernando Guerrero-Pérez, Inmaculada Peiró, José L. Vercher-Conejero, Alex Teulé, Carles Villabona" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Fernando" "apellidos" => "Guerrero-Pérez" ] 1 => array:2 [ "nombre" => "Inmaculada" "apellidos" => "Peiró" ] 2 => array:2 [ "nombre" => "José L." "apellidos" => "Vercher-Conejero" ] 3 => array:2 [ "nombre" => "Alex" "apellidos" => "Teulé" ] 4 => array:2 [ "nombre" => "Carles" "apellidos" => "Villabona" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016424000715?idApp=UINPBA00004N" "url" => "/25300164/0000007100000006/v1_202406180456/S2530016424000715/v1_202406180456/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "New approaches to refractory necrobiosis lipoidica with photodynamic therapy: Case report" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "271" "paginaFinal" => "273" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "A. López Montalbán, A. López Ávila" "autores" => array:2 [ 0 => array:3 [ "nombre" => "A." "apellidos" => "López Montalbán" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0010" ] ] ] 1 => array:4 [ "nombre" => "A." "apellidos" => "López Ávila" "email" => array:1 [ 0 => "angel.lopezmontalban1@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain" "etiqueta" => "a" "identificador" => "aff0010" ] 1 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital General Universitario Santa María del Rosell, Cartagena, Murcia, Spain" "etiqueta" => "b" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Nuevos enfoques en la necrobiosis lipoídica refractaria con terapia fotodinámica: caso clínico" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1015 "Ancho" => 1000 "Tamanyo" => 85438 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">NL lesions in the lower pretibial region: case #1 (A and B, before and after treatment with PDT; case #2 (C and D, before and after treatment with PDT).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Necrobiosis lipoidica (NL) is a rare chronic granulomatous disease of female predominance (3:1) that affects 0.3% up to 1.2% of patients with diabetes mellitus. The median age of onset is typically around the fourth to fifth decades of life, although onset starts earlier in patients with type 1 vs type 2 diabetes and nondiabetics. NL is strongly, but not exclusively, associated with diabetes mellitus. Plaques are violaceous-brown, contain an atrophic central area with yellowish-brown discoloration with telangiectasis and are often found in both lower extremities. Ulceration occurs in up to 35% of patients and is often associated with pain. NL is usually diagnosed through physical examination, yet skin biopsy can help differentiate it from diabetic dermopathy, sarcoidosis, necrobiotic xanthogranuloma or granuloma annulare.<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">1,2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Although the pathophysiology of NL remains unclear, microangiopathy may plays a key role in immunomediated vascular disruption leading to collagen degeneration.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> Histopathologically, NL is identified by horizontal palisaded neutrophilic and granulomatous inflammation and collagen degeneration occurring beneath the epidermis, and necrobiosis.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">4</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Photodynamic therapy (PDT) is a photochemotherapy based on the local application of a photosensitive compound (5-aminolaevulinic acid or methyl ester 5-aminolevulinate) and subsequent exposure to a light source of adequate wavelength. Inside target cells, photosensitizers are turned into photoactive protoporphyrin IX (PpIX) and after an incubation period (usually 3<span class="elsevierStyleHsp" style=""></span>h), PpIX is activated by an artificial light source (conventional PDT) or sunlight (daylight PDT), leading to the production of reactive oxygen species (ROS), which eventually triggers the apoptosis and necrosis of target cells, and the stimulation of an immune modulating response.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">5,6</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">We report our initial experience with 2 patients with refractory NL treated with PDT: patient #1 was a 17-year-old woman diagnosed with type 1 diabetes at the age of 6 years (case #1) with no chronic diabetes complications described to date, and currently treated anxiety as the only comorbidity, good metabolic control, and current basal-bolus insulin therapy. The patient presented with an >8-year history of a single plaque with erythematous borders and an atrophic central area with 5<span class="elsevierStyleHsp" style=""></span>cm<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>3<span class="elsevierStyleHsp" style=""></span>cm telangiectasis on her right leg in the lower pretibial region. Punch biopsy confirmed the presence f NL.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Patient #2 was a 32-year-old previously healthy woman (case #2) who presented with a 6-year history of a single annular plaque with overlying 5<span class="elsevierStyleHsp" style=""></span>cm<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>4<span class="elsevierStyleHsp" style=""></span>cm hyperpigmented telangiectatic patches on her right leg. A screening test for diabetes and diabetes-associated autoantibodies were performed while on PDT. The results did not show any alterations. Since the 2 patients underwent topical corticosteroids treatment (clobetasol propionate 0.05% cream), along with calcineurin inhibitors (pimecrolimus 1% and tacrolimus 0.1%) with no significant improvement we decided to put them on PDT. The photosensitizer was applied with an incubation period of 3<span class="elsevierStyleHsp" style=""></span>h under occlusion with 37<span class="elsevierStyleHsp" style=""></span>J/cm<span class="elsevierStyleSup">2</span> of red light at a wavelength 630<span class="elsevierStyleHsp" style=""></span>nm for 10<span class="elsevierStyleHsp" style=""></span>min. In case #1, 2 cycles of 3 sessions with an interval of 2 weeks between sessions were administered. The 2 cycles were separated by a 1-year interval. Methyl-aminolevulinate (MAL; Metvix x® ®, Galderma, Lausanne, Switzerland), a photosensitizer, and Aktilite e® CL128 lamp (Galderma, Lausanne, Switzerland) were used. The treatment was highly effective with almost complete resolution of the plaque leaving residual hypopigmentation only (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>, A and B). In case #2, we administered 2 cycles of 3 sessions with an interval of 6 weeks between sessions. The 2 cycles were separated by a 1-year interval. The photosensitizer applied was ameluz (5-aminolevulinic acid, Biofrontier laboratory, Leverkusen, Germany) and the lamp used was BF-RhodoLED®. At the end of the treatment period, a remarkable improvement with complete response was observed and the Dermatology Life Quality Index (DLQI) dropped 4 points in case #2 (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>, C and D).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">Given the unknown etiology of NL, effective treatment modalities are rare. Topical corticosteroids have been the first-line therapy of NL for decades, but are minimally effective as monotherapy shows improvements in less than half of the cases.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> Topical calcineurin inhibitors are increasingly used as alternatives or along with topical corticosteroids. Furthermore, topical calcitriol, pentoxifylline, acetylsalicylic acid, dipyridamole, ticlopidine or high-dose nicotinamide are second-line therapies with a low level of evidence. Over the past decade, the use of PDT has shown promising results as second-line therapy for refractory cases. Medical follow-up is recommended not only because of its recurrent nature but because the appearance of new skin lesions is not a rare finding.</p><p id="par0035" class="elsevierStylePara elsevierViewall">PDT is a non-invasive therapeutic procedure widely used in adult patients for the management of tumoral, inflammatory, and infectious skin diseases. In this article we reviewed our own experience with the use of off-label PDT as a second-line therapy to treat refractory cases of NL.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">5</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">Kaae et al. (2018) conducted a retrospective study on 65 NL patients treated with PDT and saw complete response in 66% of cases, with similar rates between C-PDT and DL-PDT.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">7</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Recently, the PDT technique has been used with daylight for the management of NL. López Sanz P et al. reported 1 case which resolved completely, yet with areas of residual hypopigmentation.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Summarizing the literature search, we find case series that report an overall response rate of 39% up to 100%.<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">9,10</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">The wide variety of results could be explained by the heterogeneity of the lesions, exposure time, number of cycles, periodicity between sessions, the energy applied, and the concentration of the drug.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">In conclusion, the management of NL can be challenging for diabetologists and dermatologists alike. It is remarkable how PDT could increase the success rate. Our experience shows variable but promising responses vs previous conventional therapies. However, there are no clinical trials, reports with a high level of evidence, or guidelines on the management of NL.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Funding</span><p id="par0065" class="elsevierStylePara elsevierViewall">None declared.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Authorship</span><p id="par0070" class="elsevierStylePara elsevierViewall">The authors declare that all authors have read and approved the manuscript and that the requirements for authorship have been met. Each of the people who appear as the author of the article has participated in a relevant way in the design and development of it to assume responsibility for the contents and, likewise, agree with the final version of the article.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Originality of the material</span><p id="par0075" class="elsevierStylePara elsevierViewall">The authors declare that the content of the article is original and that it has not been previously published nor is it submitted or submitted for consideration to any other publication, in whole or in part.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Informed consent</span><p id="par0080" class="elsevierStylePara elsevierViewall">Patient data does not identify the subject. Informed consent has been obtained from the patient authorizing its publication, reproduction and dissemination on paper and on the Internet in Primary Care.</p><p id="par0085" class="elsevierStylePara elsevierViewall">The authors declare that the protocols established by the health center have been followed to access the data from the medical records in order to be able to make this type of publication for dissemination purposes to the scientific community.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conflict of interest</span><p id="par0090" class="elsevierStylePara elsevierViewall">None declared.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Authorship" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Originality of the material" ] 3 => array:2 [ "identificador" => "sec0020" "titulo" => "Informed consent" ] 4 => array:2 [ "identificador" => "sec0025" "titulo" => "Conflict of interest" ] 5 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1015 "Ancho" => 1000 "Tamanyo" => 85438 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">NL lesions in the lower pretibial region: case #1 (A and B, before and after treatment with PDT; case #2 (C and D, before and after treatment with PDT).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0055" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment options for necrobiosis lipoidica: a systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Nihal" 1 => "A.S. Caplan" 2 => "M. Rosenbach" 3 => "W. Damsky" 4 => "A.R. Mangold" 5 => "B.E. Shields" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ijd.16856" "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "2023" "volumen" => "62" "paginaInicial" => "1529" "paginaFinal" => "1537" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37772666" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0060" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical features and comorbidities of patients with necrobiosis lipoidica with or without diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.A. Hashemi" 1 => "Z.O. Brown-Joel" 2 => "E. Tkachenko" 3 => "C.A. Nelson" 4 => "M.H. Noe" 5 => "S. Imadojemu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamadermatol.2018.5635" "Revista" => array:6 [ "tituloSerie" => "JAMA Dermatol" "fecha" => "2019" "volumen" => "155" "paginaInicial" => "455" "paginaFinal" => "459" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30785603" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0065" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Laser and light therapies for the treatment of necrobiosis lipoidica" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Rajabi-Estarabadi" 1 => "Divya" 2 => "J. Aickara" 3 => "M. Hirsch" 4 => "N.M. Williams" 5 => "E.L. Maranda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10103-020-03147-3" "Revista" => array:6 [ "tituloSerie" => "Lasers Med Sci" "fecha" => "2021" "volumen" => "36" "paginaInicial" => "497" "paginaFinal" => "506" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32970197" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0070" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "What is new in the histogenesis of granulomatous skin diseases?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Asai" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Dermatol" "fecha" => "2017" "volumen" => "44" "paginaInicial" => "297" "paginaFinal" => "303" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0075" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy in pediatric age: current applications and future trends" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Di Bartolomeo" 1 => "D. Altavilla" 2 => "M. Vaccaro" 3 => "F. Vaccaro" 4 => "V. Squadrito" 5 => "F. Squadrito" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Front Pharmacol" "fecha" => "2022" "volumen" => "13" "paginaInicial" => "1" "paginaFinal" => "18" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0080" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Gilaberte Y, Serra-guillén C, Elena M, Heras D, Ruiz-rodríguez R. Terapia fotodinámica en dermatología. 2006;97:83–102." ] ] ] 6 => array:3 [ "identificador" => "bib0085" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Kaae J, Philipsen PA, Wulf HC. Photodynamic therapy of necrobiosis lipoidica using methyl aminolevulinate: a retrospective follow-up study. Photodiagn Photodyn Ther. 2018;22:223–6. Available from: <a target="_blank" href="https://doi.org/10.1016/j.pdpdt.2018.04.020">https://doi.org/10.1016/j.pdpdt.2018.04.020</a>." ] ] ] 7 => array:3 [ "identificador" => "bib0090" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Daylight photodynamic therapy in necrobiosis lipoidica: a promising treatment?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "P. López Sanz" 1 => "C. Faura Berruga" 2 => "C. Guerrero Ramírez" 3 => "S. Manso Córdoba" 4 => "M.E. Alfaro Martínez" 5 => "A. García Vázquez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/phpp.12831" "Revista" => array:6 [ "tituloSerie" => "Photodermatol Photoimmunol Photomed" "fecha" => "2023" "volumen" => "39" "paginaInicial" => "294" "paginaFinal" => "295" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35996345" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0095" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Conventional photodynamic therapy for necrobiosis lipoidica: successful treatment in a series of 4 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "E. Bernia" 1 => "B. Llombart" 2 => "B. Bancalari" 3 => "A. Diago" 4 => "C. Serra-Guillén" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2019.01.022" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2020" "volumen" => "111" "paginaInicial" => "605" "paginaFinal" => "608" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32574711" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0100" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy for necrobiosis lipoidica is an unpredictable option: three cases with different results" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "T. Truchuelo" 1 => "J. Alcántara" 2 => "B. Pérez" 3 => "P. Jaén" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int J Dermatol" "fecha" => "2013" "volumen" => "52" "paginaInicial" => "1589" "paginaFinal" => "1590" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/25300164/0000007100000006/v1_202406180456/S2530016424000855/v1_202406180456/en/main.assets" "Apartado" => array:4 [ "identificador" => "72000" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Carta científica" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25300164/0000007100000006/v1_202406180456/S2530016424000855/v1_202406180456/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2530016424000855?idApp=UINPBA00004N" ]
Consulte los artículos y contenidos publicados en este medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación
Esté informado en todo momento gracias a las alertas y novedades
Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados
Endocrinología, Diabetes y Nutrición es la revista órgano de expresión de la Sociedad Española de Endocrinología y Nutrición (SEEN) y de la Sociedad Española de Diabetes (SED). La publicación recoge el apasionante progreso registrado en el conocimiento de la fisiopatología endocrina tanto en el ámbito clínico como experimental, y es un fiel exponente de los avances de esta especialidad en nuestro país. Además de las secciones Originales y Notas clínicas, en las que se publican trabajos de gran calidad elaborados por diversos centros endocrinológicos clínicos y experimentales, la revista publica artículos de Revisión y Editoriales escritos por reconocidos especialistas de la endocrinología española con el fin de actualizar conocimientos y dar a conocer los avances más relevantes en la actualidad.
Index Medicus/MEDLINE, Excerpta Medica/EMBASE, SCOPUS, Science Citation Index Expanded, Journal Citation Reports/Science Edition, IBECS
Ver másEl factor de impacto mide la media del número de citaciones recibidas en un año por trabajos publicados en la publicación durante los dos años anteriores.
© Clarivate Analytics, Journal Citation Reports 2022
SJR es una prestigiosa métrica basada en la idea de que todas las citaciones no son iguales. SJR usa un algoritmo similar al page rank de Google; es una medida cuantitativa y cualitativa al impacto de una publicación.
Ver másSNIP permite comparar el impacto de revistas de diferentes campos temáticos, corrigiendo las diferencias en la probabilidad de ser citado que existe entre revistas de distintas materias.
Ver más¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?
Are you a health professional able to prescribe or dispense drugs?
Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos